Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics Announces Executive Leadership Transition

GlobeNewswire June 29, 2022

Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

GlobeNewswire June 15, 2022

Allarity Therapeutics Reports First Quarter 2022 Financial Results

GlobeNewswire May 27, 2022

Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

GlobeNewswire May 18, 2022

Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

GlobeNewswire May 16, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

GlobeNewswire April 22, 2022

Allarity Therapeutics Provides Update on Dovitinib Program

GlobeNewswire March 15, 2022

Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA

GlobeNewswire February 18, 2022

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

GlobeNewswire January 3, 2022